During neoadjuvant immunotherapy, the appropriate timing for primary tumor resection might play a crucial role in the expansion and functionality of tumor-specific T cells (especially gp70 tetramer-specific CD8 T cells). This evidence concerns the gene CD8A and neoplasm.